Skip to main content
  1. Home
  2. All Tools
  3. Research Staff
  4. An Overview of NIH Policy

An Overview of NIH Policy

Facebook Twitter

NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research

Policy Summary:

  • Women and Minority groups must be included in NIH-funded clinical research studies
  • Women and Minority groups must be included in Phase III clinical trials & the trial must be designed to document valid analysis
  • The NIH supports appropriate outreach programs to recruit and retain women and minority groups in clinical trials

Pre Phase III Considerations:

"Did prior studies indicate significant differences between subgroups?
- Have a plan to conduct valid analyses to distinguish the significant differences between genders and/or racial/ethnic subgroups."

"Did prior studies not support significant differences between subgroups?
- Representation as subject selection standard is not required; however, inclusion and analyses is encouraged."

"Finally, if the prior studies neither supported nor negated significant differences in intervention effects between subgroups, the researcher should have a plan on how to conduct valid analyses of the intervention effect in sex/gender and/or racial/ethnic subgroups."

Policy definitions:

Human Subjects: "A living individual about whom an investigator conducting research obtains data through intervention or interaction with the individual or if identifiable private information is being used"

Valid Analysis: "A valid analysis is an unbiased assessment. In order to do a valid analysis the researcher must have a diverse participation population"

Significant Difference: "Significant difference is of clinical or public health importance, based on substantial scientific data"

Resources:

1. https://grants1.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm

2. https://grants.nih.gov/grants/funding/women_min/women_min.htm

 Research Staff